- Alnylam Pharmaceuticals
- Christopher M. Morrison, Lead Attorney for Whitehead
- David Bartel & Lab
- David I. Gindler, Max-Planck Lead Attorney
- Debra G. Josephson - Lead attorney for Utah
- Dirk Haussecker’s RNAi Blog
- Donald R. Ware, Lead Attorney for UMass
- Dr. Tuschl’s Faculty webpage
- Glenn Pfadenhauer, Lead Attorney for Whitehead
- Judge Saris
- Michael Strub, Lead Attorney for Max-Planck
- Morgan Chu, Lead Attorney for Max-Planck
- Nicholas S. Boebel - Attorney for Utah
- Phillip Sharp & Lab
- Phillip Zamore at HHMI
- Professor Brenda Bass
- RNAi.net -Coverage of the world of RNA interference
- RXi Pharmaceuticals
- Scott McConchie, Attorney for Alnylam
- Sirna Therapeutics - Merck
- Steve W. Berman - Lead attorney for Utah
- Thomas Maffei, Lead Attorney for Alnylam
- Thomas Tuschl & Lab
- Wolfgang Weiss, IP Attorney for Max-Planck
Tekmira Responds to the Counterclaim Filed by Alnylam
Tekmira Pharmaceuticals Corporation reports that Alnylam Pharmaceuticals, Inc. has filed its answer and counterclaim to the lawsuit that Tekmira originally filed on March 16, 2011.
As outlined in Tekmira’s legal complaint filed on March 16, 2011, Tekmira is suing Alnylam for actions including misappropriation and misuse of trade secrets, know-how and other confidential information.
“This filing of a counterclaim is an expected development in this litigation. We have reviewed the counterclaim and remain confident in our position. We are fully committed and prepared to pursue this lawsuit until we have a fair and satisfactory resolution. Our goal is to regain – as soon as possible – control over our proprietary LNP technology and preserve its full value,” said Dr. Mark J. Murray, Tekmira’s President and CEO.
Leave a Reply
- Cloning of Human Embryonic Stem Cells…and Human Beings - a Future Platform for Therapeutic RNAi?
- The Rise of Therapeutic Antibodies – Will RNAi Therapeutics Take As Long?
- Motion Granted - Production of the Whitehead Litigation Materials is Stayed
- Alnylam/Tekmira Lawsuits ALL Settled - Now On With Alnylam/UUtah
- Dirk Interprets Alnylam’s SEC Statement
- The Tone of the Infringment Lawsuit Filed by Alnylam and Isis Against Tekmira
- Alnylam’s Venture into Biopesticides is Not Surprising
- How the UUtah Case and the Max-Planck/ Alnylam Case v. Whitehead etal are Connected
- Brian Maffly Reports on the Battle for the Rights to siRNA in the Salt Lake Tribune
- Brief Update on the UUtah Case Against the Four Universities and Alnylam
- Perhaps Acrimony Between Tekmira and Protiva Led to Firing of the Team that Became AlCana
- Dirk and Sherk Elaborate on the Tekmira v. Alnylam Case
- Status of Tekmira Pharmaceuticals’ Lawsuit against Defendants Alnylam Pharmaceuticals and Partner Alcana Technologies
- Benitec BioPharma Likes Alnylam’s Result - A Boost for RNAi Pharmaceuticals
- Alnylam’s Stock Jumps
- May 2013 (1)
- April 2013 (1)
- January 2013 (1)
- November 2012 (2)
- October 2012 (1)
- August 2012 (4)
- July 2012 (7)
- June 2012 (14)
- May 2012 (2)
- March 2012 (2)
- February 2012 (2)
- January 2012 (3)
- December 2011 (1)
- November 2011 (2)
- October 2011 (1)
- September 2011 (10)
- July 2011 (6)
- June 2011 (4)
- May 2011 (8)
- April 2011 (7)
- March 2011 (19)
- February 2011 (18)
- January 2011 (5)
- December 2010 (1)
- November 2010 (11)
- October 2010 (31)
- September 2010 (20)
- August 2010 (13)
- July 2010 (8)
- June 2010 (26)
- May 2010 (24)
- April 2010 (10)
- March 2010 (1)
- johnleavitt on The Tone of the Infringment Lawsuit Filed by Alnylam and Isis Against Tekmira
- Steve Helton on The Tone of the Infringment Lawsuit Filed by Alnylam and Isis Against Tekmira
- Dirk Haussecker on Alnylam’s Venture into Biopesticides is Not Surprising
- andrew on Alnylam’s Venture into Biopesticides is Not Surprising
- johnleavitt on Perhaps Acrimony Between Tekmira and Protiva Led to Firing of the Team that Became AlCana
- Dirk on Status of Tekmira Pharmaceuticals’ Lawsuit against Defendants Alnylam Pharmaceuticals and Partner Alcana Technologies
- sherk on Status of Tekmira Pharmaceuticals’ Lawsuit against Defendants Alnylam Pharmaceuticals and Partner Alcana Technologies
- sherk on Status of Tekmira Pharmaceuticals’ Lawsuit against Defendants Alnylam Pharmaceuticals and Partner Alcana Technologies
- tufulipo on What the Defendants Admit in Response to UUtah’s 89 Allegations in Their 2nd Amended Complaint
- johnleavitt on Alnylam with MIT and Harvard Develop a New siRNA Delivery Method
- sherk on Alnylam with MIT and Harvard Develop a New siRNA Delivery Method
- johnleavitt on A Conversation Between Judge Saris and the Attorneys – Status Conference
- Steve_382 on A Conversation Between Judge Saris and the Attorneys – Status Conference
- john on A Tekmira v. Alnylam Discovery Hearing is Scheduled for November 16 at 2 PM
- sherk on A Tekmira v. Alnylam Discovery Hearing is Scheduled for November 16 at 2 PM
- Police: Man stabs woman, then cuts his own throat - Yankton Daily Press
- Neighbors and Friends React to Brutal Grand Island Stabbing - 1011 Home - 1011now
- Police: Man stabs woman, then cuts his own throat - Beatrice Daily Sun - Beatrice Daily Sun
- Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi ... - EON: Enhanced Online News (press release)
- Grand Island woman stabbed 20 times - News, Weather and Sports for Lincoln ... - KLKN
- Woman stabbed outside Grand Island cathedral - Omaha World-Herald
- Violence erupts at a house of worship, as Grand Island police investigate a ... - NTV
- Tekmira Highlights Ongoing Lipid Nanoparticle Technology Innovations at ... - AZoNano.com
- Tekmira Provides Corporate Update and Announces First Quarter 2013 Results - PharmaLive (press release) (subscription)
- “Love handles” melt away at the push of a button - HealthCanal.com

